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Lysophosphatidic acid (LPA, 1-acyl-glycerol-3-phosphate) plays an important role in diverse biological responses
including cell proliferation, differentiation, survival, migration, and tumor cell invasion. The most prominent source
of LPA is platelets from which it is released after thrombin activation and is assumed to be an essential function of
this lysophospholipid in cutaneous wound closure. Therefore, we examined the role of LPA on biological re-
sponses of keratinocytes. Although LPA potently enhances keratinocyte migration, it strongly induces growth
arrest of proliferating epidermal cells. Thus, LPA possesses analogous actions to transforming growth factor-b
(TGF-b), which is also released from degranulating platelets at wounded sites. In contrast to LPA, the intracellular
signaling events of TGF-b have been clearly identiﬁed and indicate that Smad3 is involved in chemotaxis and cell
growth arrest of keratinocytes induced by this cytokine. Here we show that LPA, although it does not alter TGF-b
release is capable to activate Smad3 and results in a heteromerization with Smad4 and binding of the complex to its
specific DNA-promoter elements. LPA completely fails to induce chemotaxis in Smad3-deﬁcient cells, whereas
growth inhibition is at least in part reduced. These ﬁndings indicate an essential role of Smad3 in diverse biological
properties of LPA-stimulated keratinocytes.
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Lysophosphatidic acid (LPA, 1-acyl-glycerol-3-phosphate),
one of the simplest phospholipids, has been identified as a
pluripotent biological mediator that can be produced by a
variety of cells including platelets, fibroblasts, adipocytes,
or cancer cells (Tigyi et al, 1994; Gaits et al, 1997; Pages
et al, 2000; Shida et al, 2003). The most prominent re-
sponses induced by LPA include cell proliferation, differ-
entiation, survival, chemotaxis, platelet aggregation, and
tumor cell invasion (Moolenaar, 1999, 2000). Moreover, dys-
regulation of LPA production has also been suggested in
pathophysiological processes such as cardiovascular and
neoplastic diseases (Mills et al, 2002; Osborne and Stainier,
2003). LPA evokes its multiple effects through G-protein-
coupled receptors that belong to the Edg (endothelial dif-
ferentiation gene) family, namely Edg2/LPA1, Edg4/LPA2,
and Edg7/LPA3 (Contos et al, 2000). Depending on the ex-
pression of LPA receptors and the involvement of different
G-proteins, LPA may influence a wide array of biological
responses in diverse cell types; however, control of these
complex processes is difficult to reconcile with only these
three receptors suggesting further unidentified targets of
LPA. Indeed, the transcription factor peroxisome prolifera-
tor-activated receptor g has been recognized as an intra-
cellular receptor for LPA (McIntyre et al, 2003).
The leading source of LPA are platelets from which it is
generated and released after thrombin activation (Sano
et al, 2002). Thus, serum contains micromolar concentra-
tions of the lysophospholipid, whereas levels in the plasma
are much lower (Aoki et al, 2002). For that reason, it has
been proposed that LPA is a key mediator in the regulation
of wound healing. Indeed, it has been shown that LPA pro-
motes endothelial as well as intestinal epithelial wound clo-
sure, a dynamic process that combines tissue regeneration
events with local activation of immune functions (Sturm
et al, 1999; Lee et al, 2000). Diverse cell types are involved
in these processes and modified by LPA. But there exists a
fundamental divergence between epithelial and endothelial
wound closure, although LPA strongly enhances migration
of both cell types, there is an opposing action on cell pro-
liferation. In analogy to fibroblasts and vascular smooth
muscle cells, LPA stimulates endothelial cell proliferation
(Tigyi et al, 1994; Tokumura et al, 1994; Lee et al, 2002),
whereas a cell growth arrest in intestinal epithelial cells is
observed (Sturm et al, 1999). Although a cell growth inhib-
itory effect may counteract a sufficient wound closure, it has
to be considered that LPA ameliorates further aspects of
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healing like cell surface fibronectin assembly and infiltration
of immune cells (Panetti et al, 2001; Huang et al, 2002).
Among the numerous mediators that modulate epithelial
and endothelial restitution, transforming growth factor b
(TGF-b) plays a central role as it is released in response to
many other cytokines promoting wound closure (O’Kane
and Ferguson, 1997; Sturm et al, 1999). Like LPA, TGF-b is a
strong inhibitor of epithelial cell growth, but enhances pro-
liferation of fibroblasts as well as endothelial cells (Suemori
et al, 1991; Roberts and Sporn, 1993; Dignass and Podol-
sky, 1993). It should be noted that TGF-b influences ep-
idermal cells, responsible for the reconstruction of the
cutaneous barrier, in a similar manner as epithelial cells
since migration of keratinocytes is enhanced, whereas cell
growth is inhibited (Alexandrow and Moses, 1995; Ashcroft
et al, 1999; Ashcroft and Roberts, 2000).
A disarmingly simple system has been elucidated that
mediates many diverse TGF-b responses. This system in-
cludes a family of TGF-b receptor substrates, the Smad
proteins, which translocate into the nucleus where they act
as transcription factors. Binding of TGF-b links its receptors
TbRII and TbRI activating the serine/threonine kinase func-
tion of TbRII, which then phosphorylates TbRI. This process
is followed by the anchoring of receptor-activated Smads
(R-Smads) to the TbRI kinase domain (Massague, 1998;
Tsukazaki et al, 1998; Massague, 2000). Phosphorylation on
the C-terminal SSVS motif of Smad causes a conformatio-
nal change that results in the heteromerization with Smad4
(Co-Smad) and correlates with the movement of the com-
plex from the cytoplasm to the nucleus. Here they directly or
indirectly regulate the transcription of target genes (Mass-
ague and Chen, 2000; Massague and Wotton, 2000). In hu-
man keratinocytes Smad3 was clearly identified as an
essential receptor-activated Smad protein associated with
TGF-b-induced biological responses. Knocking out Smad3
completely diminished TGF-b-induced chemotaxis and par-
tially cell growth arrest of keratinocytes (Ashcroft et al, 1999;
Ashcroft and Roberts, 2000).
The aim of this study was to characterize the effects of
LPA on critical functions of keratinocytes. Most interestingly,
LPA affects biological responses of kerationcytes like mi-
gration and proliferation in a similar manner as TGF-b.
Therefore, we aimed to analyze whether TGF-b signaling is
essential for LPA-mediated biological responses. Our re-
sults clearly indicate that LPA, like TGF-b, leads to a func-
tional activation of the TFG-b signal transducer Smad3 and
that both LPA and TGF-b receptors are involved in this
process.
Results
Modulation of keratinocyte growth and migration by
LPA Although several studies indicate that LPA is a strong
chemoattractant for various cells (Sturm et al, 1999; Lee
et al, 2000; Panetti et al, 2001), the chemotactic activity in
keratinocytes in response to LPA has not been defined.
Therefore, the effect of LPA on migration of primary human
keratinocytes was assessed in a modified Boyden chamber
using fibronectin-coated filters. As presented in Fig 1A,
keratinocytes migrated toward LPA in a concentration-
dependent and saturable manner showing a maximal effect
at 5 mM. For control purposes, the migratory effect of TGF-b
was also evaluated as this cytokine has been identified as a
potent chemoattractant for keratinocytes. Both, TGF-b and
LPA led to a comparable enhancement of migrated cells
(Fig 1A). Moreover, when keratinocytes were co-stimulated
with TGF-b and LPA in those concentrations, which did not
lead to a maximal effect, an additive migration rate was
visible (Fig 1A).
LPA has also been reported as a potent mitogen in sev-
eral cell lines and primary cell cultures. In contrast, LPA
impaired proliferation of keratinocytes in the logarithmic
growth phase in a concentration-dependent manner. A
maximal effect, which was not due to cytotoxicity, appeared
at a concentration of 10 mM leading to a decrease of
[3H]thymidine incorporation of almost 60%. Cell cycle anal-
ysis revealed an increased cell number in the G0/G1 phase
after exposure to LPA, whereas keratinocytes entering the S
phase were significantly reduced (Fig 1C). The antiprolifer-
ative effect was comparable with the action of the well
known growth inhibitory factor TGF-b (Ashcroft et al, 1999),
which served as positive control (Fig 1B). In analogy to the
migration experiments, there was an increase of cell growth
arrest, when keratinocytes were treated with both TGF-b
and LPA (Fig 1B).
Smad3 activation in response to LPA The presented re-
sults revealed analogous effects of LPA and TGF-b in
human epidermal cells. Therefore, we measured whether
treatment of keratinocytes with LPA leads to a secretion of
the cytokine TGF-b. Indeed, LPA neither enhanced peptide
levels of TGF-b nor increased latent complexes of TGF-b
over a time period of 24 h. As positive control 1a,25-di-
hydroxyvitamin D3 was used, which significantly augmented
TGF-b release after a stimulation period of 24 h (Fig 2A). To
further substantiate that LPA-induced keratinocyte migra-
tion and cell growth arrest are independent of TGF-b
release, both effects were measured under immunoneutral-
ized conditions. As presented in Fig 2B and C, LPA en-
hanced migration and induced cell growth arrest of
keratinocytes in the presence of anti-TGF-b antibodies,
whereas the effects in response to TGF-b were significantly
diminished.
In contrast to LPA, the signaling cascade of TGF-b is well
characterized, suggesting that intracellular Smad3 protein
mediates the migratory response toward TGF-b and in part
its antiproliferative properties (Ashcroft et al, 1999). To re-
veal whether LPA provokes its effects in analogy to TGF-b
via Smad3 signaling, we first determined whether Smad3 is
phosphorylated in response to LPA. Therefore, lysates from
LPA-stimulated keratinocytes were immunoprecipitated
with anti-Smad3 antibodies, and western blot analysis
was performed with anti-phosphoserine antibodies. As
shown in Fig 3A, a pronounced phosphorylation of Smad3
occurred in response to LPA, whereas its protein levels were
unaffected. The phosphorylation was visible after 10 min
and the most effective dose was 1 mM of LPA (Fig 3B). This
rapid phosphorylation of Smad3 in response to LPA con-
firms a mechanism that is independent of a LPA-mediated
TGF-b release.
Next, it was of interest to determine whether phosphor-
ylation of Smad3 by LPA leads to the heterodimerization
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with Smad4, as this process is crucial for the transloca-
tion into the nucleus. To address this, LPA-stimulated cells
were immunoprecipitated with anti-Smad3 antibodies and
immunoblotted with anti-Smad4 antibodies. Indeed, Smad4
was co-immunoprecipitated after treatment with LPA (Fig
3C). To substantiate a translocation of the complex we
measured the occurrence of both Smad proteins in the nu-
cleus. In non-stimulated nuclei Smad4 as well as Smad3
was not detectable, but both appeared in the nuclear frac-
tion, when cells were treated with LPA (Fig 3D). But it should
be mentioned that changes of the level of Smad3 and
Smad4 in the cytosol were not visible, indicating that only a
minor part of Smad proteins is translocated.
To prove the DNA-binding of the active complex, a
DNA-affinity precipitation assay was performed. Therefore,
lysates of stimulated keratinocytes were incubated with a
biotinylated oligonucleotide probe representing a tandemly
repeated CAGA Smad3/Smad4 binding element (Nishihara
et al, 1999). Treatment with LPA resulted in an increased
binding of the Smad3/Smad4 complex to the oligonucleo-
tide (Fig 3E ). The DNA binding was specific as a biotiny-
lated scrambled fragment did not precipitate Smad3
protein. Moreover, competition experiments using biotiny-
lated and non-biotinylated CAGA sequences together re-
sulted in a slight decrease of the Smad3 band (Fig 3E ).
Consistent with the LPA-dependent Smad3 activation, TGF-
b induced Smad3/Smad4 complex formation, nuclear trans-
location of the complex, and promoter binding (Fig 3C–E ).
Involvement of Smad3 in LPA-induced migration and
cell growth arrest These results clearly demonstrate the
activation of Smad3 by LPA, but do not indicate an essential
role of this signaling pathway for biological responses.
Therefore, we examined whether keratinocyte migration
and proliferation were modified by Smad3 disruption.
Keratinocytes were isolated from newborn wild-type or
Smad3(ex8/ex8)-deficient mice. In analogy to cells of human
origin, wild-type keratinocytes strongly migrated to both
LPA and TGF-b. Most interestingly, Smad3(/) keratin-
ocytes, which showed a normal migration rate toward se-
rum, were not responsive toward LPA and TGF-b (Fig 4A).
These results confirm the essential migratory role of this
signal transducer for both molecules.
Proliferation measurements also revealed an inhibitory
effect of LPA and TGF-b on growth of wild-type keratin-
ocytes. The antiproliferative property of LPA but not of TGF-
b, however, was less pronounced than in human cells
(Fig 4B). Thus, a maximal effect appeared at a concentration
of 5 mM LPA leading to a significant decrease (po0.05) of
Figure1
LPA increases migration but inhibits proliferation of human kera-
tinocytes. Chemotactic migration of keratinocytes in response to a
gradient of LPA, TGF-b, or LPA/TGF-b was measured in a modified
Boyden chamber as described. Values are expressed as percentage of
control and are the mean  SEM from at least three experiments, each
run in triplicate (A). Cells were incubated with the indicated concen-
trations of LPA, TGF-b, or LPA/TGF-b for 72 h and pulsed with [3H]thy-
midine. Incorporation into DNA was determined as described under
‘‘Materials and Methods’’. Data are expressed as percentage of control
and are the mean  SEM of results of at least four experiments (B). For
cell cycle analysis keratinocytes were incubated for 24 h with the in-
dicated concentrations of LPA. Then, RNA was digested and DNA was
labeled with PI and staining was determined by flow cytometry. Data
are expressed as mean  SEM from three independent experiments
(C).po0.05 and po0.001 indicate a statistically significant differ-
ence versus unstimulated control cells.
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[3H]thymidine incorporation of only 30%, whereas TGF-b (2
ng per mL) reduced proliferation rates by more than 70%.
Nonetheless, a reduced sensitivity to growth inhibition
occurred in keratinocytes from Smad3-deficient mice,
when stimulated with TGF-b or LPA (Fig 4B). These data
clearly indicate that Smad3 is at least in part responsible
for the antiproliferative property of not only TGF-b but also
of LPA.
LPA induces growth inhibition and migration as well as
Smad-activation through Gi/o-coupled receptors Most of
the effects of LPA are mediated through G-protein-coupled
receptors, namely LPA13 (Moolenaar et al, 1997; Contos
et al, 2000). But the expression of these receptors in ep-
idermal cells until now has not been characterized. RT-PCR
indicated that mRNA transcripts for all three LPA receptors,
LPA1, LPA2, and LPA3, exist in human primary keratinocytes
as well as in intact skin (Fig 5C). To evaluate coupling of LPA
receptors to G-proteins, the GDP/GTP exchange was
measured by the use of [35S]GTPgS, and indeed, LPA en-
hanced binding of [35S]GTPgS to G-proteins of isolated
membranes indicating that human keratinocytes express
functionally active LPA receptors (data not shown).
To address, whether LPA receptors are essential for
both biological responses of LPA and Smad3 activation,
we assessed these actions after pre-treatment with pert-
ussis toxin (PTX). Our findings indicate that PTX prevented
cell growth arrest and caused a strong inhibition of keratin-
ocyte migration (Fig 5A, B). In similar, treatment of keratin-
ocytes with PTX also completely diminished Smad3 phos-
phorylation indicating that the phosphorylation event is a
consequence of LPA-receptor stimulation (Fig 5D). To ad-
dress whether also TGF-b receptors are involved in LPA-
induced activation of Smad signaling, cells were treated
with SB431542, which specifically blocks the ATP-binding
site of the TbRI (Laping et al, 2002), followed by the meas-
urement of Smad3 phosphorylation. As expected, Smad3
activation by TGF-b was completely abolished in the pres-
ence of SB431542 (Fig 5E ). Accordingly, LPA was not able
to phosphorylate Smad3, when cells were pre-treated with
the inhibitor, indicating the involvement of TGF-b receptors
to mediate LPA-induced Smad signaling (Fig 5E ).
Figure 2
LPA induces migration
and cell growth arrest
of keratinocytes inde-
pendent from TGF-b
secretion. Cells were
stimulated with LPA (1
mM) or 1a,25-dihydroxy-
vitamin D3 (1,25VD3, 100
nM) for the indicated
time periods. Then latent
and active TGF-b was
measured in the super-
natant as described
under ‘‘Materials and
Methods’’. Values are ex-
pressed as total amount
of TGF-b  SEM from
three experiments (A).
Chemotactic migration
and [3H]thymidine incor-
poration in response to
LPA or TGF-b was meas-
ured in the presence of
anti-TGF-b- or IgG-con-
trol antibodies (25 mg
per mL). Values are ex-
pressed as percentage
of control and are the
mean  SEM from at
least three experiments
(B, C).
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Discussion
These data indicate that LPA enhances migration and in-
hibits cell growth of keratinocytes. Since intracellular targets
of LPA have not been well defined, we clearly provide ev-
idence that Smad-signaling is essential for LPA-mediated
biological responses. Thus, LPA not only induces an acti-
vation of Smad3 but also fails to mediate migration and in
part growth inhibition, when Smad3 is eliminated.
Rapid migration and proliferation of keratinocytes are
essential to improve wound healing after various forms of
cutaneous injury. A multitude of biological mediators and
growth factors are formed and stored in human platelets,
which in response to an injury are released at the wounded
site (Lee, 2000). One of these factors is LPA suggesting a
potential relevance for the wound-healing process (Sturm
et al, 1999; Lee et al, 2000; Moolenaar, 2000). Indeed, here
we show that migration and proliferation events of keratin-
ocytes are modulated by this lysophospholipid. Exogenou-
sly added LPA promotes cell migration and inhibits
proliferation of human keratinocytes. These data are con-
sistent with intestinal wound healing as similar effects of
LPA on intestinal epithelial cells have been observed (Sturm
et al, 1999). Our data, however, are unexpected as it has
been suggested that LPA possesses proliferative properties
in primary keratinocytes (Piazza et al, 1995). Therefore, it
should be considered that these studies were performed
with quiescent keratinocytes and moreover a slight increase
only occurred in the millimolar range. Our results clearly
indicate, that lower micromolar levels of LPA potently inhibit
growth of proliferating keratinocytes. The concentration, in
which chemotaxis and cell growth inhibition by LPA takes
place, is in agreement with serum levels, which have been
estimated in the range of 2–20 mM of LPA (Aoki et al, 2002).
Interestingly, LPA possesses analogous actions on cell
proliferation and migration in epithelial and epidermal cells
Figure 3
LPA induces Smad3 activation in human keratinocytes. Cells were incubated with 1 mM LPA for different time periods (A) or with the indicated
concentrations of LPA for 30 min (B). After cell lysis, Smad3 protein was immunoprecipitated with anti-Smad3-antbodies and western blot analysis
was performed with anti-Smad3- (lower panel) or anti-phosphoserine (anti-P-ser) antibodies (upper panel) as described under ‘‘Materials and
Methods’’ (A, B). Cells were treated with control vehicle, TGF-b (2 ng per mL) or LPA (1 mM) for the indicated periods. After immunoprecipitation with
normal goat IgG (IgG-control) or anti-Smad3 antibodies, western blot analysis was performed. The top blot was developed using anti-Smad4-, and
the bottom blot with anti-Smad3 antibodies (C). Keratinocytes were stimulated with control vehicle, TGF-b (2 ng per mL) or LPA (1 mM) for 45 min
followed by the isolation of nuclei as described under ‘‘Materials and Methods’’. After protein determination, lysates of nuclei (200 mg protein per
sample) were immunoprecipitated with anti-Smad3 antibodies, followed by immunoblotting. The top blot was developed using anti-Smad4- and the
bottom blot with anti-Smad3 antibodies (D). Lysates of TGF-b (2 ng per mL, 30 min), LPA (1 mM, 30 min) ore control vehicle stimulated cells were
incubated with a biotinylated double-stranded DNA (30 pM) composed of three tandemly repeated CAGA sequences. To control the specificity of
the oligonucleotides, stimulated lysates were incubated with biotinylated scramled DNA fragments (30 pM). For competition control, lysates were
incubated with 30 pM of biotinylated and 30 pM of non-biotinylated three tandemly repeated CAGA sequences. DNA-bound proteins were
precipitated with streptavidin–agarose and western blot analysis using anti-Smad3 antibodies was performed (E ). Smad3 was detected at 56 kDa
and Smad4 at 66 kDa. All results were confirmed in three independent experiments.
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as the related lysophospholipid sphingosine 1-phosphate
and the cytokine TGF-b, which are derived from blood
platelets (Dignass and Podolsky, 1993; Roberts et al, 1990;
Vogler et al, 2003). Measurement of peptide levels eluci-
dated that LPA does not modulate epidermal cell functions
through the secretion of TGF-b. This corresponds with
studies by Sturm et al (1999), which show that proliferation
and migration of epithelial cells by LPA are independent of a
release of TGF-b. TGF-b is known to mediate its chemo-
tactic response and its cell growth inhibition in keratin-
ocytes by the activation of the TGF-b receptor substrate
Smad3 (Ashcroft et al, 1999; Ashcroft and Roberts, 2000).
Most recently several studies indicate that Smad proteins
can be activated in a TGF-b-independent way. Such an ac-
tivation of Smad proteins has been shown for insulin-like
growth factor binding protein-3 as well as for epidermal
growth factor (EGF) and hepatocyte growth factor (de Ca-
estecker et al, 1998; Fanayan et al, 2000; Fanayan et al,
2002; Firth and Baxter, 2002). These molecules are capable
to stimulate Smad2 phosphorylation in breast cancer cells
even in the absence of endogenous or exogenous TGF-b.
Thus, it was of interest to figure out, whether LPA may also
modulate Smad protein activity in a ligand-independent
fashion. Indeed, here we clearly present evidence that LPA
phosphorylates the Smad3 protein, which results in a het-
eromerization with Smad4, translocation into the nucleus,
and the binding to target genes. The crucial role of Smad3
for biological actions of LPA becomes visible after abroga-
tion of this transducing molecule as both the migratory re-
sponse and the cell growth arrest are completely lost and
reduced, respectively.
Next it was of interest to further elucidate the mechanism
underlying the Smad activation by the lysophospholipid.
Although intracellular targets of LPA have been discussed,
most biological responses are mediated through the acti-
vation of the G-protein-coupled LPA receptors (Mills et al,
2002; Takuwa et al, 2002). But to our knowledge the ex-
pression of LPA receptors in primary keratinocytes has not
been examined. Here, we show that not only all LPA re-
ceptors are present in human keratinocytes but also con-
tribute to the activation of TGF-b signaling. Thus, Smad
phosphorylation is completely abolished in the presence of
PTX. In accordance also LPA-induced migration and cell
growth arrest are sensitive to this toxin. Moreover, our
results clearly indicate also an involvement of TbRI in
LPA-induced Smad3 activation. These data suggest a cross-
communication between LPA- and TGF-b receptors. In-
deed, such a receptor interaction has also been described
to contribute to Smad activation by insulin-like growth
factor binding protein-3 as it needs the existence of type I
and II TGF-b receptors. In contrast, Smad activation by
EGF also occurs in TGF-b receptor deficient cells (de
Caestecker et al, 1998; Fanayan et al, 2000, 2002; Firth and
Baxter, 2002).
Indeed, several lines of evidence also support the finding
that LPA receptors build functional heterodimers with other
plasma membrane receptors. Initially, it was found that in
Rat-1 fibroblasts LPA induces a rapid phosphorylation of
the EGF receptor suggesting that LPA effects are executed
through the stimulation of receptor tyrosine kinase activity
(Hordijk et al, 1994). Actually, in analogy to LPA, the EGF
receptor plays a central role in regulating cell proliferation,
differentiation, and migration (Brown, 1995). Internalization
of the EGF-receptor represents an important facet for the
control of mitogenic responses (Kim et al, 2003). Thus, it has
Figure 4
LPA-mediated migration and cell growth arrest is inhibited by the
abrogation of Smad3 signaling. Chemotactic migration of keratin-
ocytes isolated from wild-type and Smad3(/) mice was measured in
response to a gradient of LPA (concentrations as indicated), TGF-b (2
ng per mL) or serum (10%) in a chemotaxis chamber as described (A).
Wild-type and Smad3(/) keratinocytes were treated with TGF-b or
LPA in the indicated concentrations for 24 h and pulsed with [3H]thy-
midine. Then incorporation into DNA was determined as described in
‘‘Materials and Methods’’ (B). Values are percentage of control  SEM
from at least three experiments. po0.05 and po0.001 indicate a
statistically significant difference versus unstimulated control cells.
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been shown that the EGF-receptor is removed from the cell
surface not only following stimulation with EGF, but also in
response to stimulation of LPA receptors (Kim et al, 2003).
Several mechanisms have been discussed how LPA recep-
tors induce an activation of the EGF receptor. Thus,
stimulation of the EGF receptor involves activation of mem-
brane-bound metalloproteinases, which, in response, induce
the release of heparin-EGF from its latent membrane-span-
ning precursors (Yan et al, 2002). But EGF-receptor trans-
activation by LPA receptors may also occur independently
of metalloproteinases. Accumulating evidence suggests
that c-Src tyrosine kinase activity mediates EGF receptor
activation downstream of LPA receptors as this kinase is
activated in reponse to LPA, and moreover, has been shown
to directly phosphorylate and activate the receptor tyrosine
kinase (Biscardi et al, 1999; Kim et al, 2003). Additionally, it
has been suggested that transactivation of receptor tyro-
sine kinases by LPA receptors is a more general phenom-
enon, which is not restricted to only EGF receptors. Thus,
ligand-independent activation of platelet-derived growth
factor receptor is essential to mediate the mitogenic activity
of LPA (Herrlich et al, 1998).
In summary, we present data that show a novel cross-
talk between LPA receptors and TGF-b signaling and further
Figure 5
Expression of LPA receptors in human keratinocytes and intact skin and their involvement in LPA-mediated functions. The mRNA of cultured
keratinocytes or intact skin was isolated, reverse transcribed and amplified as described in ‘‘Materials and Methods’’. PCR products of cultured
keratinocytes (left band) and intact skin (right band) were size-fractionated in an agarose gel, and visualized by ethidium bromide staining. PCR
results were confirmed by two more independent experiments (C). Human keratinocytes were pre-treated with control vehicle or 200 ng per mL PTX
for 3 h. Afterwards, growth inhibition (A), chemotaxis (B) and Smad3 phosphorylation (D) in response to the indicated concentrations of LPA was
determined. Keratinocytes were pre-incubated with SB431542 (10 mM) for 30 min. After treatment with LPA (1 mM) or TGF-b (2 ng per mL), Smad3
phosphorylation was detected (E). Values of migration and proliferation assays are percentage of control  SEM from at least three experiments.
po0.05 and po 0.001 indicate a statistically significant difference versus unstimulated control cells. Similar results of Smad3 phosphorylation
were obtained in two further experiments.
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on indicate the essential role of this pathway for biological
responses of LPA. It is of interest that TGF-b signaling is
involved in physiological and pathophysiological processes
such as wound healing or hyperproliferative skin diseases.
Owing to their transactivation effects, drug development of
LPA agonists or antagonists might present a novel method
to regulate such biological responses.
Materials and Methods
Chemicals Specific primers (LPA13) were synthesized at Tib Mo-
lbiol (Berlin, Germany). [methyl-3H]Thymidine (35 Ci/mmol), and
[35S]-GTPgS (1000 Ci per mmol) were purchased from Amersham
Pharmacia Biotech (Freiburg, Germany). TGF-b, PTX, protein G
plus agarose, molecular weight markers, sodium dodecyl sulfate
(SDS)-sample buffer, and dithiothreitol were from Calbiochem (Bad
Soden, Germany), poly dI-dC from Roche Diagnostics (Mannheim,
Germany). Goat polyclonal anti-Smad3-, goat polyclonal anti-
Smad4- antibodies, normal goat IgG, anti-goat and anti-rabbit IgG-
horseradish peroxidase were purchased from Santa Cruz Biotech-
nology (Santa Cruz, California). Rabbit polyclonal anti-phospho-
serine antibody and goat anti-TGF-b1 antibodies were obtained
from Zymed Laboratories (San Francisco, California), LumiGlo
reagent and peroxide from New England Biolabs (Beverly,
Massachusetts). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide, aprotinin, bovine serum albumin, collagen-1, deoxycholic
acid, Dulbecco’s Modified Eagle’s Medium, Eagle’s Minimal Es-
sential Medium, eosin, EDTA, fetal bovine serum, fibronectin,
GIEMSA, hematoxilen, HEPES, b-glycerophosphate, LPA, leu-
peptin, nonidet P-40, penicillin/streptomycin, pepstatin, phenyl-
methylsulfonylfluoride (PMSF), potassium glycine, SB431542,
SDS, sodium fluoride, sodium orthovanadate, streptavidin seph-
arose, sucrose, trichloroacetic acid, Tris, Triton X-100, and trypsin
were purchased from Sigma-Aldrich (Taufkirchen, Germany). HE-
PES buffer and calcium- and magnesium-free phosphate-buffered
saline (PBS) were purchased from Invitrogen (Karlsruhe, Germany).
1a,25-Dihydroxyvitamin D3 was a gift from Leo Pharmaceuticals
(Ballerup, Denmark). Keratinocyte basal medium, epidermal growth
factor (EGF), insulin, hydrocortisone, bovine pituitary extract,
gentamicin sulfate, and amphotericin B were from Cell Systems
(St Katharinen, Germany).
Keratinocyte culture To isolate human keratinocytes, juvenile
foreskin was incubated at 41C in a solution of 0.25% trypsin and
0.2% EDTA for 20 h and trypsinization was terminated by addition
of ice-cold Dulbecco’s Modified Eagle’s Medium containing 10%
fetal bovine serum. Keratinocytes were separated, washed with
PBS and centrifuged. The pellet was resuspended in keratinocyte
growth medium that was prepared from keratinocyte basal medi-
um by the addition of 0.1 ng per mL recombinant EGF, 5.0 mg per
mL insulin, 0.5 mg per mL hydrocortisone, 0.15 mM Ca2þ , 30 mg
per mL bovine pituitary extract, 50 mg per mL gentamicin sulfate,
and 50 ng per mL amphotericin B. Keratinocytes were pooled from
several donors and only used in the second or third passage.
Murine keratinocytes were isolated from PCR-genotyped
Smad3 wild-type and knockout newborn mice as recently report-
ed (Yang et al, 1999). Skin of sacrified mice was numbered and
disinfected by iodine solution. Mice were washed three times in
70% ethanol and tails from each mouse were removed for RT-PCR.
Entire skin was mechanically separated and incubated at 41C in a
solution of 0.25% trypsin and 0.2% EDTA for 20 h. According to the
results of the RT-PCR, the epidermal layers of homozygote Smad3-
knockout- and wild-type mice were pooled separately and ho-
mogenized. The cell suspensions were centrifuged, washed with
PBS and resuspended in growth medium that was prepared from
Eagle’s Minimal Essential Medium by the addition of 8% of fetal
bovine serum, 0.2 mM Ca2þ and 1% penicillin/streptomycin. The
next day, medium was switched to Eagle’s Minimal Essential
Medium/serum containing 0.05 mM Ca2þ . The protocol used in
this study was approved by the National Cancer Institute Animal
Care and Use Committee and was in accordance with the
guidelines of the Institute of Laboratory Animal Resources,
National Research Council.
Abrogation of Smad3 Smad3(ex8/ex8) mice were generated by
targeted disruption of the Smad3 gene by homologous recombi-
nation using a pLoxpneo cassette (Yang et al, 1999). Targeted
embryonic stem-cell clones were microinjected into C57BL/6
blastocysts to obtain germline transmission. Mice heterozygous
for the targeted disruption were intercrossed to produce ho-
mozygous offspring. Keratinocytes were isolated from wild-type or
Smad3-deficient homozygous mice. Genotypes were determined
by PCR. For detection of wild-type and Smad3ex8/þ mice the
primer sequences 50-CCACTTCATTGCCATATGCCCTG-30 (located
50 to the deletion) and 50-CCCGAACAGTTGGATTCACACA-30
(located within the deletion) were used. Smad3(/) mice were
identified using the primer located to the 50deletion and a primer
specific for the pLoxpneo cassette (50-CCAGACTGCCTTGG-
GAAAAGC-30).
Reverse-transcription and ampliﬁcation by PCR The mRNAs of
human keratinocytes or intact skin were isolated by QuickPrep
Micro mRNA Purification Kit (Amersham Biosciences, Freiburg,
Germany) according to the manufacturer’s instructions. One mi-
crogramm of mRNA was reverse transcribed (Superscript reverse
transcriptase, Invitrogen) in the presence of 1 pmol of a 25–30 mer
oligo(dT) primer. Based upon the nucleotide sequences of the hu-
man LPLR family, oligonucleotide primer pairs were prepared
(LPA1: 5
0-CCC AAC CAA CAG GAC TGA CT-30, 50-GGT CCA GAA
CTA TGC CGA GA-30, LPA2: 50-CCC AAC CAA CAG GAC TGA CT-
30, 50-GAG CCC TTA TCT CTC CCC AC-30; LPA3: 50-GGA CAC CCA
TGA AGC TAA TG-30, 50-TCT GGG TTC TCC TGA GAG AA-30). PCR
amplification was carried out in a Thermocycler (T Gradient, What-
man Biometra, Go¨ttingen, Germany) using the Thermoprime Plus
polymerase (Advanced Biotechnologies, Columbia, Maryland) un-
der following cycling conditions: (1) 941C for 1 min; (2) 941C for 30
s; (3) 551C for 30 s; (4) 721C for 1 min; (5) repeat of steps 2–4 for 30
cycles; (6) 721C for 2 min; and (7) 41C for 1 s. PCR products were
size-fractionated in a 2% agarose gel, and visualized by ethidium
bromide staining.
Membrane preparation and [35S]-GTPcS-binding assay Kera-
tinocytes were washed with ice-cold PBS, scraped in a buffer
containing 20 mM Tris (pH 7.4), 500 mM PMSF, 1 mg per mL each
leupeptin, aprotinin, and 0.5 mg per mL pepstatin and homoge-
nized by passing through a 28-gauge needle for 10 times. The
homogenate was centrifuged for 5 min at 5000  g and the supe-
rnatant was spun for 40 min at 43 000  g. Ten micrograms pro-
tein/assay were incubated for 45 min in a buffer containing 20 mM
Tris (pH 7.4), 5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM
PMSF, 1 mg per mL each leupeptin, aprotinin, 0.5 mg per mL peps-
tatin, 3 mM GDP, 50 pM [35S]-GTPgS, and different concentrations
of LPA. The samples were rapidly filtered on GF/B glass microfiber
filters (Whatman, Kent, UK) presoaked in a buffer [20 mM Tris (pH
7.4), 10 mM MgCl2, 100 mM NaCl, 1 mM b-mercaptoethanol]. The
filters were washed three times and radioactivity was determined in
a scintillation counter.
Measurement of TGF-b secretion Keratinocytes (4  104 cells
per mL) were stimulated with LPA over a time period of 24 h. As
positive control, 1a,25-dihydroxyvitamin D3 was used. Then levels
of TGF-b in the supernatant were quantified by selective ELISA kits
following the instructions of the manufacturer (Amersham Pharma-
cia Biotech). For measurement of latent complexes of TGF-b, acti-
vation was accomplished by acid treatment. Therefore, 0.5 mL of
cell culture supernatants were treated with 0.1 mL of 1 M HCl, incu-
bated for 10 min, and then neutralized with 0.1 mL of 1.2 M NaOH/
0.5 M HEPES. Samples were analyzed by an ELISA reader from
Merlin (Bornheim, Germany). The detection limit was 4 pg per mL.
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Immunoprecipitation of Smad proteins and western blot anal-
ysis Keratinocytes were seeded in six-well plates and cultured for
24 h. After a 2 h medium switch to HEPES buffer (1 M), cells were
treated with TGF-b or LPA in different concentrations and time
periods. To finish the stimulation, cells were rinsed twice with
ice-cold PBS and harvested in RIPA buffer (50 mM Tris/HCl, pH
7.5, 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholic acid,
0.1% SDS), containing protease inhibitors (1 mM PMSF, 1mM
EDTA, 1 mg per mL leupeptin, 1 mg per mL aprotinin and 1 mg per
mL pepstatin) and phosphatase inhibitors (1 mM sodium ortho-
vanadate, 50 mM NaF and 40 mM b-glycerophosphate). Lysates
were centrifuged at 14,000  g for 30 min and 100 mg of lysate
protein was immunoprecipitated overnight at 41C with 0.2 mg anti-
Smad3 antibodies, followed by a precipitation with 10 mL protein G
plus agarose at 41C for 90 min. After four washes with complete
RIPA buffer, the immunoprecipitates were eluted by boiling for
5 min in 60 mL SDS sample buffer (100 mM Tris/HCl, pH 6.8, 4%
SDS, 0.2% bromophenol blue, 20% glycerol, 200 mM di-
thiothreitol) and separated by SDS/PAGE. Gels were blotted over-
night onto PVDF membranes. After blocking with 5% non-fat dry
milk (for anti-Smad3 and anti-Smad4) or 3% bovine serum albumin
(for anti-phosphoserine) in Tris-buffered saline/Tween-20 (0.1%)
overnight at 41C. Membranes were incubated with anti-Smad3-,
anti-Smad4-, or anti-phosphoserine antibodies (each 0.2 mg per
mL) for 2 h at room temperature. The blots were washed three
times in Tris-buffered saline/Tween followed by incubation with the
secondary antibodies (anti-goat IgG- and anti-rabbit IgG-horse-
radish peroxidase) for 1 h. After washing, the blots were developed
according to the manufacturer’s protocol.
Isolation of nuclei Nuclei were isolated as described by Bunce
et al (1988). Briefly, keratinocytes were washed with PBS, scraped
into PBS and then centrifuged at 5000  g for 5 min. Cells were
resuspended in 400 mL of the following buffer (10 mM HEPES, pH
7.5, 5 mM MgCl2, 15 mM KCl, 1 mM PMSF) at 5  106 cells per
mL, frozen in liquid nitrogen, thawed rapidly at 371C, and then
passed 15 times through a 25-gauge needle. The homogenate
was layered on top of 200 mL of a sucrose gradient (50% sucrose
in buffer A) and centrifuged at 15,000  g for 3 min. Only
intact nuclei pelleted through the cushion, as confirmed by light
microscopy. Nuclei were lysed in 100 mL of complete RIPA
buffer by seven freeze–thawing cycles. To determine the purity of
the nuclei lysate, the activity of a specific marker enzyme for
endoplasmic reticulum, a-glucosidase II, was measured as de-
scribed by Fujimoto et al (1976). After protein determination,
lysates of nuclei (200 mg protein/sample) were immunoprecipitated
with anti-Smad3 antibodies. The immunoprecipitates were
eluted and separated by SDS/PAGE. Then western blot analysis
was performed by the use of anti-Smad3- and anti-Smad4 anti-
bodies.
Binding of the Smad3/Smad4 complex to biotinylated DNA Hu-
man keratinocytes were plated into 100 mm dishes (1  106 cells
per dish). Cells of 30%–40% confluence were stimulated, rinsed
twice with ice-cold PBS and harvested into lysis buffer (20 mM Tris/
HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 5 mM EDTA), which
was supplemented with 1 mM PMSF and 1 mg per mL aprotinin,
leupeptin and pepstatin. Lysate protein (1 mg) was incubated at
41C for 1 h with a biotinylated double-stranded DNA (30 pM) com-
posed of three-tandemly repeated CAGA sequences in the pres-
ence of 12 mg of poly dI-dC (50Bio-TCGAGAGCCAGACAAGG
AGCCAGACAAGGAGCCAGACACTCCAG-30 50-CTCGAGTGTCTG
GCTCCTTGTCTGGCTCCTTGTCTGGCTCTCGA-30). For control
experiments, lysates were incubated with a non-specific biotiny-
lated double-stranded DNA fragment of scrambled nucleotides
(5-Bio-TCG AGA GCT AGA TAA GGA GCT AGA TAA GGA GCT AGA
TAC TCG AG, 50-GAG TAT CTA GCT CCT TAT CTA GCT CCT TAT
CTA GCT CTC GA). For competition control, lysates were incu-
bated with 30 pM of biotinylated and 30 pM of non-biotinylated
three-tandemly repeated CAGA sequences. DNA-bound proteins
were precipitated with 80 mL of streptavidin–agarose at 41C for
30 min, washed several times with lysis buffer and eluted by boiling
for 5 min in 50 mL SDS sample buffer for electrophoresis and
western blot analysis using anti-Smad3 antibodies (Nishihara et al,
1999).
DNA synthesis, cell cycle and cytotoxicity analysis Keratin-
ocytes (4  104 cells per well) were grown in 24-well plates for 24
h. Then medium was replaced by fresh keratinocyte growth me-
dium and cells were incubated with TGF-b (2 ng per mL) or the
indicated concentrations of LPA for 72 h and pulsed with 1 mCi of
[methyl-3H]thymidine per well. After 23 h, the medium was re-
moved and cells were washed twice each with PBS and ice-cold
trichloroacetic acid (5%). The precipitated material was dissolved
in 0.3 N NaOH-solution and incorporated [methyl-3H]thymidine
was determined in a scintillation counter (MicroBeta Plus, Wallac
Oy, Turku, Finland).
For cell cycle analysis a cycle test plus DNA reagent kit (Becton
and Dickinson, Heidelberg, Germany) was used. Keratinocytes
were fixed, RNA was digested and DNA was labeled with prop-
idium iodide according to the manufacturer’s instructions. Staining
was determined by flow cytometry using a FACScalibur (Becton
and Dickinson).
For the measurement of cytotoxicity, keratinocytes (8  104
cells per well) were seeded into 24-well plates for 24 h and incu-
bated with LPA for 24 h at 371C in 5% CO2. After the addition
of 100 mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide solution (5 mg per mL) per well for 4 h at 371C the supe-
rnatants were removed and the formazan crystals were solubilized
in 1 mL of dimethyl sulfoxide. The optical density was measured at
540 nm using a scanning microplate spectrophotometer (Multiscan
Plus, Labsystems, Helsinki, Finland).
Migration assay Chemotaxis of human keratinocytes in response
to a gradient of serum, LPA or TGF-b was measured in a modified
Boyden chamber with fibronectin-coated filters (Wang et al, 1999).
Cells were added to the upper well of the chamber. The lower
chamber contained LPA in the indicated concentration. As control
for the chemotactic response TGF-b (2 ng per mL) was used. Cells
that had migrated through the membrane were fixed, stained by
GIEMSA and counted.
Murine keratinocytes were cultured until a confluence of ap-
proximately 30%–40%, trypsinized, washed and resuspended in
serum-free Eagle’s Minimal Essential Medium. They were added to
the upper well of a chemotaxis chamber which was separated from
the serum-, TGF-b-, or LPA-supplemented test medium by a fibr-
onectin/collagen-I-coated membrane. Cells that had migrated
through the membrane after 5 h at 371C were stained with ethanol
for 1 min, hematoxylene and eosin each for 1 min and counted.
Each value represents the average number of cells migrated from
triplicate wells.
Statistical analysis Data are expressed as the mean  SEM of
results from at least three experiments, each run in triplicate.
Statistics were performed using Student’s t test. po0.05 and
po0.001 indicate a statistically significant difference versus
control experiments.
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